Introduction: Gastric cancer remains one of the leading causes of cancer-related mortality worldwide, especially in regions such as Northern Brazil, where incidence and mortality rates remain high. Correa's cascade describes the gastric carcinogenesis model for Lauren’s intestinal-type adenocarcinoma, involving chronic gastritis, atrophy, intestinal metaplasia (IM), dysplasia, and ultimately, adenocarcinoma. In this context, the identification of precursor lesions and their association with Helicobacter pylori infection becomes relevant for planning screening and prevention strategies. Objectives: This study aimed to investigate the frequency of H. pylori infection and gastric precursor lesions in patients undergoing upper gastrointestinal endoscopy at the João de Barros Barreto University Hospital, as well as to statistically analyze progression patterns based on longitudinal follow-up. Methods: This is a retrospective and prospective cohort study including 4,137 unique patients who underwent 4,958 biopsy-associated endoscopic procedures between 2019 and 2024. Patients with histopathological findings of gastritis, atrophy, intestinal metaplasia, and/or dysplasia were included. Data were collected from electronic medical records and analyzed using R and Python software. Results: Among the evaluated patients, 845 (20.4%) presented with intestinal metaplasia, 839 (20.3%) with atrophy, 26 (0.6%) with dysplasia, and 102 (2.5%) with gastric adenocarcinoma. H. pylori infection was identified in 1,732 exams. Among 596 patients with sequential procedures, the average interval between biopsies was 16.2 months. A statistically significant association was found between “always detected” H. pylori status and progression to intestinal metaplasia (p < 0.01). The mean progression time was 20.1 months, being significantly longer in patients with H. pylori subsequently not detected. The progression rate to dysplasia was 1.9%. Conclusion: In conclusion, the prevalence of gastric precursor lesions was high in the studied population, with a relevant risk of progression. Persistent H. pylori infection was associated with lesion development. The application of OLGA and OLGIM systems proved feasible for risk stratification, reinforcing the need for national risk-based screening guidelines.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
